@article{f5a2e19187574e4db8592ec6fd95f084,
title = "In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types",
abstract = "Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to evaluate tumor biology of rare subtypes. Here, we provide an in-depth comprehensive characterization of a new PDX model for MBC, TU-BcX-4IC. TU-BcX-4IC is a clinically aggressive tumor exhibiting rapid growth in vivo, spontaneous metastases, and elevated levels of cell-free DNA and circulating tumor cell DNA. Relative chemosensitivity of primary cells derived from TU-BcX-4IC was performed using the National Cancer Institute (NCI) oncology drug set, crystal violet staining, and cytotoxic live/dead immunofluorescence stains in adherent and organoid culture conditions. We employed novel spheroid/organoid incubation methods (Pu·MA system) to demonstrate that TU-BcX-4IC is resistant to paclitaxel. An innovative physiologically relevant system using human adipose tissue was used to evaluate presence of cancer stem cell-like populations ex vivo. Tissue decellularization, cryogenic-scanning electron microscopy imaging and rheometry revealed consistent matrix architecture and stiffness were consistent despite serial transplantation. Matrix-associated gene pathways were essentially unchanged with serial passages, as determined by qPCR and RNA sequencing, suggesting utility of decellularized PDXs for in vitro screens. We determined type V collagen to be present throughout all serial passage of TU-BcX-4IC tumor, suggesting it is required for tumor maintenance and is a potential viable target for MBC. In this study we introduce an innovative and translational model system to study cell–matrix interactions in rare cancer types using higher passage PDX tissue.",
keywords = "Collagen, Extracellular matrix, Metaplastic breast carcinoma, Patient-derived xenograft, Triple negative breast cancer",
author = "Matossian, {M. D.} and T. Chang and Wright, {M. K.} and Burks, {H. E.} and S. Elliott and Sabol, {R. A.} and H. Wathieu and Windsor, {G. O.} and Alzoubi, {M. S.} and King, {C. T.} and Bursavich, {J. B.} and Ham, {A. M.} and Savoie, {J. J.} and K. Nguyen and M. Baddoo and E. Flemington and O. Sirenko and Cromwell, {E. F.} and Hebert, {K. L.} and F. Lau and R. Izadpanah and H. Brown and S. Sinha and J. Zabaleta and Riker, {A. I.} and K. Moroz and L. Miele and Zea, {A. H.} and A. Ochoa and Bunnell, {B. A.} and Collins-Burow, {B. M.} and Martin, {E. C.} and Burow, {M. E.}",
note = "Funding Information: We acknowledge and thank Krewe de Pink for their financial support of this project and dedication to support breast cancer patients in the local New Orleans community. We acknowledge the Tulane University Department of Pathology for contributions of organ processing and immunohistochemistry staining for the metastasis studies of our work. Funding Information: We acknowledge and thank Krewe de Pink for their financial support of this project and dedication to support breast cancer patients in the local New Orleans community. We acknowledge the Tulane University Department of Pathology for contributions of organ processing and immunohistochemistry staining for the metastasis studies of our work. Funding Information: This work was supported by grants from National Institute of Health (NIH) (Grants No. R01-CA125806-04 (MEB), 1R15CA176496-01A1 (MEB) and R01-CA174785-A1 (BMC-B)). This work was also supported in part by U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2022",
month = jan,
doi = "10.1007/s12094-021-02677-8",
language = "English",
volume = "24",
pages = "127--144",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "1",
}